Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide and Goserelin in Ovarian, Fallopian Tube, or Peritoneal Carcinoma
NCT00012090Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2000
- Primary completion
- Apr 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bicalutamide and goserelin in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Time-to-treatment failure. Started Sep 2000; status: completed.
02
Drugs
bicalutamidegoserelin
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00012090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012090.